Picard Medical, Inc.
Close on Oct 19, 2026
- Market cap
- $28.67M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | Apr 22, 2026 | Before market open | $1.10M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | $1.19M | $-0.19 | – |
Press releases
Announcements Picard Medical filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Picard Medical Receives NYSE American Acceptance of Compliance Plan
Listing notice · Other events · EX-99.1 to Form 8-K
Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
Other events · EX-99.1 to Form 8-K/A
PRESENTATION TRANSCRIPT (JULY 2, 2026)
Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED JULY 2, 2026
Other events · EX-99.1 to Form 8-K
PRESENTATION DATED JULY 2, 2026
Other events · EX-99.2 to Form 8-K
2026 — Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), parent company of
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical / SynCardia Reports First Quarter 2026 Financial Results
Results of operations · Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Medical / SynCardia Reports Revenue Growth
Results of operations · EX-99.1 to Form 8-K
Medical Reports Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medical / SynCardia to Present its Next-Generation Emperor Total Artificial Heart Technology at the
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical / SynCardia Highlight Second Successful
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical / SynCardia Announce Successful Four-Year Bridge to Transplant with
Regulation FD disclosure · EX-99.1 to Form 8-K
Picard Medical / SynCardia Highlight Total Artificial Heart
Regulation FD disclosure · EX-99.1 to Form 8-K
/ SynCardia to Host Annual Business Update Featuring Key Opinion Leaders and Patient Testimonial
Regulation FD disclosure · EX-99.1 to Form 8-K
Picard Medical / SynCardia Showcases Leadership in Total Artificial Heart Therapy at Technology and
Regulation FD disclosure · EX-99.1 to Form 8-K
to Participate in Inaugural “Hands-On Training Day” at the Technology and Heart Failure Therapeutics Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
/ SynCardia Featured on the Cruxx of MedTech Podcast
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Announces Up to $50 Million Senior Secured Debt Financing
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Marks Public Company Milestone by Ringing the NYSE Opening Bell
Regulation FD disclosure · EX-99.1 to Form 8-K
Patient Living a World-Record of Over Eight Years with the SynCardia Total Artificial Heart
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Picard Medical, Inc. and SynCardia Systems LLC CEO to Present at CSI Focus D-HF 2025 in Frankfurt, Germany
Regulation FD disclosure · EX-99.1 to Form 8-K
Picard Medical to Present the Next Generation Fully Implantable SynCardia Total Artificial Heart at ISMCS 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
SynCardia Completes First In Vivo Implantations of
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Picard Issues Statement on Intraday Stock Price
Regulation FD disclosure · EX-99.1 to Form 8-K
Picard Medical, Inc. Announces Exercise of Underwriters’ Over-Allotment
Other events · EX-99.1 to Form 8-K
Picard Medical, Inc. Announces Pricing of $17 Million Initial Public Offering
Material agreement · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Picard Medical, Inc. Announces Closing of $17 Million Initial Public Offering
Material agreement · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K